Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box
- PMID: 21945105
- DOI: 10.1016/j.metabol.2011.07.014
Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box
Abstract
Familial hypercholesterolemia (FH) is a dominantly inherited disorder principally due to mutations in the low-density lipoprotein (LDL) receptor that classically cause markedly elevated plasma LDL cholesterol concentrations and premature coronary heart disease (CHD). However, elevated plasma LDL cholesterol alone does not fully account for the increase or variation in risk of CHD. We propose a hypothetical model for the role of postprandial dyslipoproteinemia based on the overproduction and decreased catabolism of triglyceride-rich lipoproteins, which may be a consequence of LDL receptor deficiency. Expression of postprandial dyslipoproteinemia in FH may also depend on the type of pathogenic gene variants and on coexistent conditions, particularly obesity and insulin resistance. Further research is required to investigate our model proposed and to test whether treating postprandial dyslipoproteinemia decreases CHD risk in FH incremental to standard therapy.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.Dan Med Bull. 2002 Nov;49(4):318-45. Dan Med Bull. 2002. PMID: 12553167 Review.
-
The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies.Int J Cardiol. 2013 Oct 3;168(3):1811-8. doi: 10.1016/j.ijcard.2013.06.069. Epub 2013 Jul 29. Int J Cardiol. 2013. PMID: 23907036
-
High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia.Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2422-7. doi: 10.1161/01.atv.20.11.2422. Arterioscler Thromb Vasc Biol. 2000. PMID: 11073847
-
Familial hypercholesterolemia and triglyceride metabolism.Int J Cardiol. 2011 Mar 17;147(3):349-58. doi: 10.1016/j.ijcard.2010.08.009. Epub 2010 Sep 9. Int J Cardiol. 2011. PMID: 20826022 Review.
-
Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French-Canadian pediatric population.Pediatrics. 1995 Aug;96(2 Pt 1):239-46. Pediatrics. 1995. PMID: 7630677
Cited by
-
The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia.Curr Atheroscler Rep. 2020 Sep 1;22(11):64. doi: 10.1007/s11883-020-00884-2. Curr Atheroscler Rep. 2020. PMID: 32870376 Free PMC article. Review.
-
Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.Int J Angiol. 2021 Mar;30(1):22-28. doi: 10.1055/s-0041-1722875. Epub 2021 Feb 18. Int J Angiol. 2021. PMID: 34025093 Free PMC article. Review.
-
Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism.Nutrients. 2022 Apr 3;14(7):1503. doi: 10.3390/nu14071503. Nutrients. 2022. PMID: 35406116 Free PMC article. Review.
-
Postprandial Hyperlipemia is an Indication for Additional Risk in Sitosterolemia.J Atheroscler Thromb. 2018 Dec 1;25(12):1183-1184. doi: 10.5551/jat.ED104. Epub 2018 Oct 11. J Atheroscler Thromb. 2018. PMID: 30305464 Free PMC article. No abstract available.
-
Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort.J Mol Neurosci. 2014 Jun;53(2):150-7. doi: 10.1007/s12031-014-0238-2. Epub 2014 Mar 6. J Mol Neurosci. 2014. PMID: 24599757
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous